Together with our findings that TWEAK treatment induced NIK expression and promoted NIK-dependent glioblastoma cell invasion, these results suggest that therapy-induced inhibition of NIK should be considered as a potential determinant of treatment efficacy in the context of glioblastoma. This evidence concerns the gene MAP3K14 and glioblastoma.